Rimas J. Orentas, PhD, Seattle Children’s Research Institute, Seattle, WA, discusses the development of chimeric antigen receptor (CAR) T-cell therapies targeted against IL1RAP for the treatment of Ewing’s sarcoma. Preliminary studies of IL1RAP CAR-T in vivo indicated that novel approaches to enhancing efficacy are necessary. Furthermore, the role of the microenvironment and its impact on CAR-T cell therapy requires further investigation. This interview took place at the virtual American Association for Cancer Research (AACR) Annual Meeting 2021.
Rimas J. Orentas, PhD, has received research support from Lentigen, a Miltenyi Biotec Company; and has participated in a consultancy role for Umoja Biopharma.